Ovarian Hyperstimulation Syndrome and Cabergoline

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome (OHSS).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital; Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital
• Treatments: Cabergoline

Criteria

Inclusion Criteria:

• Development of more than 14 leading follicles larger than 10 mm and serum estradiol more than 3000 pg/ml at the end of ovulation induction with long luteal ovulation induction protocol.

• Having the criteria of PCOS

Exclusion Criteria:

• Not having the inclusion criteria.